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Background: Galectin-3 and N-terminal segment of B-type natriuretic peptide pro-hormone (NT-proBNP) are associated with a higher risk of death 
in acute and chronic heart failure patients. Furthermore, NT-proBNP provides prognostic information in patients undergoing transcatheter aortic 
valve implantation (TAVI). The aim of the present study was to determine the prognostic value of galectin-3 and NT-proBNP in patients undergoing 
TAVI within a one-year follow-up period.
methods: Consecutive patients (n=184) with aortic stenosis undergoing elective transfemoral TAVI were included. Blood samples were collected 
before and 1 day after TAVI. Galectin-3 and NT-proBNP were quantified in serum using immunoassays. Patient follow-up was for 1 year.
results: Nineteen (10.3%) patients died within 1 year after hospital discharge. There were no differences in baseline characteristics between 
deceased and surviving patients. Galectin-3 levels were similar at baseline in patients who died and those who survived (21.2 ng/mL [14.2-
32.8] vs. 18.2 ng/mL [14.3-23.8], respectively; P=0.09), whereas NT-proBNP levels at baseline were higher in patients who died (3,392.0 ng/L 
[1,710.0-15,118.0] vs. 1,819.0 ng/L [817.8-4,920.5]; P=0.008). Patients who died had higher galectin-3 (24.4 ng/mL [14.5-39.2] vs. 18.4 ng/
mL [14.4-25.0]; P=0.007) and NT-proBNP (4,608.0 ng/L [3,099.0-10,153.0] vs. 2,520.0 ng/L [1,162.0-4,751.0]; P=0.003) levels after TAVI. In 
particular, male patients (n=8) who died had higher galectin-3 levels after TAVI (25.0 ng/mL [13.6-37.7] vs. 36.9 ng/mL [18.0-52.2]; P<0.001). 
The multivariate cox regression analysis revealed that the risk of mortality was higher if galectin-3 was increased 1 day after TAVI (hazard ratio 1.15; 
P=0.001). Compared with NT-proBNP (AUC 0.803 [95% CI 0.59-1.02; P=0.03]), the level of galectin-3 1 day after TAVI best predicted mortality, 
especially in men (AUC 0.828 [95% CI 0.55-1.11; P=0.01]).
conclusion: Galectin-3 provides prognostic information predicting mortality within a 12-month period when measured 1 day after TAVI. These 
findings provide information about this biomarker that could be used for risk stratification in patients undergoing TAVI.
